343 related articles for article (PubMed ID: 32621535)
1. FDG-PET/CT after two cycles of R-CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome - final result of a UK National Cancer Research Institute prospective study.
Mikhaeel NG; Cunningham D; Counsell N; McMillan A; Radford JA; Ardeshna KM; Lawrie A; Smith P; Clifton-Hadley L; O'Doherty MJ; Barrington SF
Br J Haematol; 2021 Feb; 192(3):504-513. PubMed ID: 32621535
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Value of
Michaud L; Bantilan K; Mauguen A; Moskowitz CH; Zelenetz AD; Schöder H
J Nucl Med; 2023 Apr; 64(4):536-541. PubMed ID: 36549918
[TBL] [Abstract][Full Text] [Related]
3. The prognostic value of bone marrow retention index and bone marrow-to-liver ratio of baseline 18F-FDG PET/CT in diffuse large B-cell lymphoma.
El-Azony A; Basha MAA; Almalki YE; Abdelmaksoud B; Hefzi N; Alnagar AA; Mahdey S; Ali IM; Nasr I; Abdalla AAEM; Yousef HY; Zaitoun MMA; Elsayed SB; Nada MG; Amin MI; Hassan RM; Ali SA; Dawoud TM; Aly SA; Algazzar YH; Abdelhamed H
Eur Radiol; 2024 Apr; 34(4):2500-2511. PubMed ID: 37812294
[TBL] [Abstract][Full Text] [Related]
4. Four cycles of R-CHOP followed by two applications of rituximab based on negative interim PET/CT: an analysis of a prospective trial.
Jin J; Ji D; Xia Z; Xue K; Zhang Q; Liu Y; Cao J; Hong X; Gu JJ; Guo Y; Lv F
BMC Cancer; 2022 Apr; 22(1):403. PubMed ID: 35418080
[TBL] [Abstract][Full Text] [Related]
5.
Minamimoto R; Fayad L; Vose J; Meza J; Advani R; Hankins J; Mottaghy F; Macapinlac H; Heinzel A; Juweid ME; Quon A
Eur J Nucl Med Mol Imaging; 2021 Aug; 48(9):2883-2893. PubMed ID: 33909086
[TBL] [Abstract][Full Text] [Related]
6. The prognostic value of PET/CT evaluation with Deauville score on the recurrence and survival in diffuse large B-cell lymphoma: a multi-institutional study of KROG 17-02.
Lee JW; Oh D; Eom KY; Kim JH; Kim WC; Chung MJ; Lee JH
Clin Exp Metastasis; 2020 Feb; 37(1):125-131. PubMed ID: 31555945
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of interim ¹⁸F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma.
Yang DH; Min JJ; Song HC; Jeong YY; Chung WK; Bae SY; Ahn JS; Kim YK; Bom HS; Chung IJ; Kim HJ; Lee JJ
Eur J Cancer; 2011 Jun; 47(9):1312-8. PubMed ID: 21334197
[TBL] [Abstract][Full Text] [Related]
8. Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07).
Mamot C; Klingbiel D; Hitz F; Renner C; Pabst T; Driessen C; Mey U; Pless M; Bargetzi M; Krasniqi F; Gigli F; Hany T; Samarin A; Biaggi C; Rusterholz C; Dirnhofer S; Zucca E; Martinelli G
J Clin Oncol; 2015 Aug; 33(23):2523-9. PubMed ID: 26150440
[TBL] [Abstract][Full Text] [Related]
9. Value of
Jiang C; Teng Y; Chen J; Wang Z; Zhou Z; Ding C; Xu J
Ann Nucl Med; 2020 Dec; 34(12):911-919. PubMed ID: 33057996
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma.
Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G
Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875
[TBL] [Abstract][Full Text] [Related]
11. Positron emission tomography-adapted therapy in low-risk diffuse large B-cell lymphoma: results of a randomized, phase III, non-inferiority trial.
Shi Q; He Y; Yi HM; Mu RJ; Jiang XF; Fu D; Dong L; Qin W; Xu PP; Cheng S; Song Q; Chen SJ; Wang L; Zhao WL
Cancer Commun (Lond); 2023 Aug; 43(8):896-908. PubMed ID: 37403255
[TBL] [Abstract][Full Text] [Related]
12. Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP.
Pregno P; Chiappella A; Bellò M; Botto B; Ferrero S; Franceschetti S; Giunta F; Ladetto M; Limerutti G; Menga M; Nicolosi M; Priolo G; Puccini B; Rigacci L; Salvi F; Vaggelli L; Passera R; Bisi G; Vitolo U
Blood; 2012 Mar; 119(9):2066-73. PubMed ID: 22234681
[TBL] [Abstract][Full Text] [Related]
13. Predicting primary treatment failure using interim FDG-PET scanning in diffuse large B-cell lymphoma.
Wight J; Wai SH; Shen E; Lee ST; Berlangieri S; Fancourt T; Hawkes E; Hannah A; Leung T; Chong G
Eur J Haematol; 2021 Oct; 107(4):475-483. PubMed ID: 34240453
[TBL] [Abstract][Full Text] [Related]
14. Prognostic models integrating quantitative parameters from baseline and interim positron emission computed tomography in patients with diffuse large B-cell lymphoma: post-hoc analysis from the SAKK38/07 clinical trial.
Zucca E; Cascione L; Ruberto T; Facchinelli D; Schär S; Hayoz S; Dirnhofer S; Giovanella L; Bargetzi M; Mamot C; Ceriani L
Hematol Oncol; 2020 Dec; 38(5):715-725. PubMed ID: 32947651
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of complete remission status at end-of-treatment FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: systematic review and meta-analysis.
Adams HJ; Nievelstein RA; Kwee TC
Br J Haematol; 2015 Jul; 170(2):185-91. PubMed ID: 25833790
[TBL] [Abstract][Full Text] [Related]
16. Brain glucose metabolism in diffuse large B-cell lymphoma patients as assessed with FDG-PET: impact on outcome and chemotherapy effects.
Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
Acta Radiol; 2016 Jun; 57(6):733-41. PubMed ID: 26297729
[TBL] [Abstract][Full Text] [Related]
17. Interim fluorine-18 fluorodeoxyglucose PET-computed tomography and cell of origin by immunohistochemistry predicts progression-free and overall survival in diffuse large B-cell lymphoma patients in the rituximab era.
de Oliveira Costa R; Hallack Neto A; Siqueira S; Lage LA; de Paula HM; Coutinho AM; Pereira J
Nucl Med Commun; 2016 Oct; 37(10):1095-101. PubMed ID: 27281359
[TBL] [Abstract][Full Text] [Related]
18. Limited role of interim PET/CT in patients with diffuse large B-cell lymphoma treated with R-CHOP.
Yoo C; Lee DH; Kim JE; Jo J; Yoon DH; Sohn BS; Kim SW; Lee JS; Suh C
Ann Hematol; 2011 Jul; 90(7):797-802. PubMed ID: 21181163
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of interim FDG PET-CT in patients older than 60 years with diffuse large B-cell lymphoma treated by PMitCEBO plus rituximab. Comparison between Deauville 5-point scale and International Harmonization Project criteria.
Lombion N; Robin P; Tempescul A; LE Roux PY; Schick U; Guillerm G; Ianotto JC; Berthou C; Salaün PY; Abgral R
Q J Nucl Med Mol Imaging; 2021 Dec; 65(4):402-409. PubMed ID: 35133099
[TBL] [Abstract][Full Text] [Related]
20. The role of 18F-FDG PET/CT in patients with diffuse large B-cell lymphoma after radioimmunotherapy using 131I-rituximab as consolidation therapy.
Choi JH; Lim I; Byun BH; Kim BI; Choi CW; Kang HJ; Shin DY; Lim SM
PLoS One; 2022; 17(9):e0273839. PubMed ID: 36156599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
